Nephrology Director:MARUYAMA Shoichi (Professor)

We provide medical care for all diseases related to the kidney with the latest therapies

We treat various renal diseases after carefully examining information based on accurate evidence and obtaining full understanding from the patient and family.

Medical Care System

Our department consists of about 20 full-time and part-time doctors. Medical care is provided mainly by professors who are nephrology specialists. We hold a conference twice a week and determine the course of treatment.

Target Diseases

All diseases related to the kidney including renal disease such as nephritis, nephrotic syndrome, chronic kidney disease (CKD), acute kidney injury (AKI), hypertensive renal disorder, diabetic nephropathy, polycystic kidney disease, autoimmune disease disorder, systemic vasculitis syndrome and management after renal transplantation and electrolyte and acid-base balance disorder.

Strong Fields

We are actively involved in renal pathological diagnosis, renal replacement therapy, and new immunosuppressive therapies using MMF, rituximab, etc. and alpha-glucosidase replacement therapy for diseases such as refractory nephrotic syndrome, collagen disorder, and hereditary diseases.

Clinical Results

Annual number of inpatients: 501; number of pathological diagnoses by renal biopsy: 933 (our hospital: 112, affiliated facilities: 821); number of patients in whom dialysis was newly introduced: 56 (hemodialysis: 45, peritoneal dialysis 11); number of patients who underwent PD+HD combination therapy: 4; other patients (plasma exchange therapy and selective blood cell component adsorption therapy; total number of patients: 140).

Specialized Outpatient Clinic

The outpatient clinic for peritoneal dialysis, the outpatient clinic for CKD, the outpatient clinic for polycystic kidney disease, and the outpatient clinic for kidney transplantation are now open to the public.

Advanced Medicine and Research

We are involved in laparoscopic renal biopsy (in cooperation with Urology) for high-risk patients, research on renal regeneration using adipose stem cells, development of urinary biomarkers for nephrotic syndrome, acute renal disorders, and lupus nephritis development of antihypertensive drugs using RAS inhibitory molecules, and elucidation of the mechanism of peritoneal fibrosis.